Neoleukin Therapeutics Return On Equity vs. Debt To Equity

NLTXDelisted Stock  USD 0.69  0.01  1.43%   
Based on Neoleukin Therapeutics' profitability indicators, Neoleukin Therapeutics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Neoleukin Therapeutics' ability to earn profits and add value for shareholders.
For Neoleukin Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Neoleukin Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Neoleukin Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Neoleukin Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Neoleukin Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Please note, there is a significant difference between Neoleukin Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neoleukin Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neoleukin Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Neoleukin Therapeutics Debt To Equity vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Neoleukin Therapeutics's current stock value. Our valuation model uses many indicators to compare Neoleukin Therapeutics value to that of its competitors to determine the firm's financial worth.
Neoleukin Therapeutics is regarded second in return on equity category among its peers. It is regarded fourth in debt to equity category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neoleukin Therapeutics' earnings, one of the primary drivers of an investment's value.

Neoleukin Debt To Equity vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Neoleukin Therapeutics

Return On Equity

 = 

Net Income

Total Equity

 = 
-0.38
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Neoleukin Therapeutics

D/E

 = 

Total Debt

Total Equity

 = 
0.11 %
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Neoleukin Debt To Equity Comparison

Neoleukin Therapeutics is currently under evaluation in debt to equity category among its peers.

Neoleukin Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Neoleukin Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Neoleukin Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Neoleukin Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Neoleukin Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Neoleukin Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.

Neoleukin Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Neoleukin Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Neoleukin Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Neoleukin Therapeutics' important profitability drivers and their relationship over time.

Use Neoleukin Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neoleukin Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neoleukin Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Neoleukin Therapeutics Pair Trading

Neoleukin Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Neoleukin Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neoleukin Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neoleukin Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neoleukin Therapeutics to buy it.
The correlation of Neoleukin Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neoleukin Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neoleukin Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neoleukin Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Neoleukin Therapeutics position

In addition to having Neoleukin Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Buywrite ETFs Thematic Idea Now

Buywrite ETFs
Buywrite ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Buywrite ETFs theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Buywrite ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Other Consideration for investing in Neoleukin Stock

If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Stocks Directory
Find actively traded stocks across global markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Money Managers
Screen money managers from public funds and ETFs managed around the world
Fundamental Analysis
View fundamental data based on most recent published financial statements
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets